FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: Tripsitter Clinic Ltd. (the “Issuer”).

Trading Symbol: KETA Number of Outstanding Listed Securities: 33,290,868

Date: February 15, 2023

# Report on Business

1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.

**TripSitter Clinic Ltd., through its wholly-owned subsidiary TripSitter Clinic Corp, is at the forefront of two emerging sectors: telehealth and psychedelic medicine. The Company’s consultative virtual clinic, TripSitter.Clinic, is a SaaS platform that provides care, monitoring and coaching while connecting patients with licensed physicians in the United States who can evaluate for a prescribed psychedelic treatment program of therapeutic low-dose ketamine medication. TripSitter is not a primary care physician (PCP). TripSitter.Clinic requires prospective patients to provide a diagnosis from their PCP along with other health information to their chosen TripSitter physician during the initial intake process. When a patient is approved for treatment by their physician, TripSitter.Clinic connects the patient with experts who also use the platform to consult and coordinate with the patient and their physician.**

1. Provide a general overview and discussion of the activities of management.

# Management actively continued initiatives to optimize its service offering to patients, sourcing new doctors, expanding its service offering to new jurisdictions.

1. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

# No such matters to report.

1. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

# No such matters to report.

1. Describe any new business relationships entered into between the Issuer, the Issuer’s affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

# No such matters to report.

1. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer’s affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

# No such matters to report.

1. Describe any acquisitions by the Issuer or dispositions of the Issuer’s assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

# No such matters to report.

1. Describe the acquisition of new customers or loss of customers.

# No such matters to report.

1. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

# No such matters to report.

1. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

# No such matters to report.

1. Report on any labour disputes and resolutions of those disputes if applicable.

# No such matters to report.

1. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

# No such matters to report.

1. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

# No such matters to report.

1. Provide details of any securities issued and options or warrants granted.

|  |  |  |  |
| --- | --- | --- | --- |
| **Security** | **Number Issued** | **Details of Issuance** | **Use of Proceeds(1)** |
| **Common Shares** | **1,000,000** | **Asset Acquisition – Reconscious Medical** | **N/A** |
| **Warrants** | **1,000,000** | **Asset Acquisition**   1. **500,000 at USD$0.20 until Feb 28, 2026** 2. **500,000 at USD$0.50 until Feb 28, 2026** | **N/A** |
| **Common Shares** | **2,000,000** | **Debt Settlement – of USD$76,244.93 3rd party services** | **N/A** |
| **Warrants** | **1,000,000** | **Debt Settlement – at $0.05 until Aug 1, 2024** | **N/A** |

**(1)State aggregate proceeds and intended allocation of proceeds.**

1. Provide details of any loans to or by Related Persons.

# No such matters to report.

1. Provide details of any changes in directors, officers or committee members.

# During January 2023, Alex Somjen resigned as a director of the Company.

1. Discuss any trends which are likely to impact the Issuer including trends in the Issuer’s market(s) or political/regulatory trends.

**Management expects the adoption of telehealth and online mental health services to continue to grow.**

**Please refer to the “Risk Factors” section of the CSE Form 2A Listing Statement dated November 25, 2021 which is available on SEDAR at** [**www.sedar.com**](http://www.sedar.com/) **and on the Exchange's website at** [**www.thecse.com**](http://www.thecse.com/)**.**

**Certificate Of Compliance**

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated February 15, 2023

Dr. John Huber Name of Director or Senior Officer

“Dr. John Huber” Signature

Chief Executive Officer Official Capacity

|  |  |  |
| --- | --- | --- |
| ***Issuer Details*** Name of Issuer Tripsitter Clinic Ltd. | For Month End January 2023 | Date of Report YY/MM/DD 23/02/15 |
| Issuer Address  77 King Street West - Suite 700 | | |
| City/Province/Postal Code Toronto, ON M5K 1G8 | Issuer Fax No. ( ) | Issuer Telephone No.  416-480-2488 |
| Contact Name  Dr. John Huber | Contact  CEO | Contact Telephone No.  416-480-2488 |
| Contact Email Address  [dr.huber@tripsitter.clinic](mailto:dr.huber@tripsitter.clinic) | Web Site Address  <https://www.tripsitter.clinic> | |